Efficacy and Safety of Biosimilar CT-P17 Versus Reference Adalimumab in Subjects With Rheumatoid Arthritis

24-Week Results From a Randomized Study

Jonathan Kay; Janusz Jaworski; Rafal Wojciechowski; Piotr Wiland; Anna Dudek; Marek Krogulec; Slawomir Jeka; Agnieszka Zielinska; Jakub Trefler; Katarzyna Bartnicka-Maslowska; Magdalena Krajewska-Wlodarczyk; Piotr A. Klimiuk; Sang Joon Lee; Yun Ju Bae; Go Eun Yang; Jae Kyoung Yoo; Daniel E. Furst; Edward Keystone

Disclosures

Arthritis Res Ther. 2021;23(51) 

In This Article

Conclusions

In conclusion, demonstration of equivalent efficacy and comparable safety and immunogenicity of CT-P17 to EU-adalimumab in this study support the ongoing clinical evaluation of CT-P17 as an adalimumab biosimilar.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....